Literature DB >> 24132735

Distribution of metastatic sites in patients with prostate cancer: A population-based analysis.

Giorgio Gandaglia1, Firas Abdollah, Jonas Schiffmann, Vincent Trudeau, Shahrokh F Shariat, Simon P Kim, Paul Perrotte, Francesco Montorsi, Alberto Briganti, Quoc-Dien Trinh, Pierre I Karakiewicz, Maxine Sun.   

Abstract

BACKGROUND: There is few data on what constitutes the distribution of metastatic sites in prostate cancer (PCa). The aim of our study was to systematically describe the most common sites of metastases in a contemporary cohort of PCa patients.
METHODS: Patients with metastatic PCa were abstracted from the Nationwide Inpatient Sample (1998-2010). Most common metastatic sites within the entire population were described. Stratification was performed according to the presence of single or multiple (≥ 2 sites) metastases. Additionally, we evaluated the distribution of metastatic sites amongst patients with and without bone metastases.
RESULTS: Overall, 74,826 patients with metastatic PCa were identified. The most common metastatic sites were bone (84%), distant lymph nodes (10.6%), liver (10.2%), and thorax (9.1%). Overall, 18.4% of patients had multiple metastatic sites involved. When stratifying patients according to the site of metastases, only 19.4% of men with bone metastases had multiple sites involved. Conversely, among patients with lymph nodes, liver, thorax, brain, digestive system, retroperitoneum, and kidney and adrenal gland metastases the proportion of men with multiple sites involved was 43.4%, 76.0%, 76.7%, 73.0%, 52.2%, 60.9%, and 76.4%, respectively. When focusing exclusively on patients with bone metastases, the most common sites of secondary metastases were liver (39.1%), thorax (35.2%), distant lymph nodes (24.6%), and brain (12.4%).
CONCLUSIONS: Although the majority of patients with metastatic PCa experience bone location, the proportion of patients with atypical metastases is not negligible. These findings might be helpful when planning diagnostic imaging procedures in patients with advanced PCa.
© 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  bone metastases; metastatic disease; prostate cancer; sites of metastases

Mesh:

Year:  2013        PMID: 24132735     DOI: 10.1002/pros.22742

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  116 in total

1.  Novel Long Non-coding RNA lncAMPC Promotes Metastasis and Immunosuppression in Prostate Cancer by Stimulating LIF/LIFR Expression.

Authors:  Wei Zhang; Xiaolei Shi; Rui Chen; Yasheng Zhu; Shihong Peng; Yifan Chang; Xinwen Nian; Guang'an Xiao; Ziyu Fang; Yaoming Li; Zhexu Cao; Lin Zhao; Guang Liu; Yinghao Sun; Shancheng Ren
Journal:  Mol Ther       Date:  2020-06-15       Impact factor: 11.454

2.  Validation of TNM classification for metastatic prostatic cancer treated using primary androgen deprivation therapy.

Authors:  Yoshifumi Kadono; Takahiro Nohara; Satoru Ueno; Kouji Izumi; Yasuhide Kitagawa; Hiroyuki Konaka; Atsushi Mizokami; Mizuki Onozawa; Shiro Hinotsu; Hideyuki Akaza; Mikio Namiki
Journal:  World J Urol       Date:  2015-06-06       Impact factor: 4.226

3.  Giant renal metastasis from prostate cancer mimicking renal cell carcinoma.

Authors:  Neslihan Kurtul; Sefa Resim; Sezen Koçarslan
Journal:  Turk J Urol       Date:  2018-07

4.  Case series - Peritoneal and port-site metastasis following roboticassisted radical prostatectomy.

Authors:  Ellen O'Connor; Brennan Timm; Bodie Chislett; Jiasian Teh; Nathan Lawrentschuk; Declan G Murphy; Damien Bolton
Journal:  Can Urol Assoc J       Date:  2021-01       Impact factor: 1.862

5.  Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.

Authors:  Raquel Perez-Lopez; Joaquin Mateo; Helen Mossop; Matthew D Blackledge; David J Collins; Mihaela Rata; Veronica A Morgan; Alison Macdonald; Shahneen Sandhu; David Lorente; Pasquale Rescigno; Zafeiris Zafeiriou; Diletta Bianchini; Nuria Porta; Emma Hall; Martin O Leach; Johann S de Bono; Dow-Mu Koh; Nina Tunariu
Journal:  Radiology       Date:  2016-11-22       Impact factor: 11.105

6.  Development and validation of prognostic nomograms for patients with metastatic prostate cancer.

Authors:  Wei-Dong Jiang; Ping-Cheng Yuan
Journal:  Int Urol Nephrol       Date:  2019-07-09       Impact factor: 2.370

7.  Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis.

Authors:  Jacqueline E Reilly; Jeffrey D Neighbors; Huaxiang Tong; Michael D Henry; Raymond J Hohl
Journal:  Clin Exp Metastasis       Date:  2015-06-13       Impact factor: 5.150

Review 8.  Malignant invasion of the central nervous system: the hidden face of a poorly understood outcome of prostate cancer.

Authors:  Eliane Gouvêa de Oliveira Barros; Nathalia Meireles Da Costa; Celia Yelimar Palmero; Luis Felipe Ribeiro Pinto; Luiz Eurico Nasciutti; Antonio Palumbo
Journal:  World J Urol       Date:  2018-07-06       Impact factor: 4.226

9.  Mitochondrial DNA mutations in prostate cancer bone metastases.

Authors:  Christopher G Keith; Rebecca S Arnold; John A Petros
Journal:  J Nat Sci       Date:  2015-08

10.  Diagnostic Performance of 18F-Fluciclovine in Detection of Prostate Cancer Bone Metastases.

Authors:  Albert Chau; Peter Gardiner; Patrick M Colletti; Hossein Jadvar
Journal:  Clin Nucl Med       Date:  2018-07       Impact factor: 7.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.